SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1436)	7/13/2002 5:06:13 PM
From: Biomaven	of 1477

Interesting. A couple of years back (late 2000) at a neuro conference presentation they (SKB at the time) said they had no plans to take this compound into the clinic. A quick google search now reveals this from a respiratory conference in May 2001: Dr DW Hay (GlaxoSmithKline, USA) outlined work with the p38 kinase inhibitor, SB 239063, in models that represent different pathological aspects of COPD. This compound reduced neutrophil infiltration, reduced inflammatory cytokine production (such as interleukin-6) and reduced matrix metalloproteinase-9 activity thus supporting the therapeutic potential of SB 239063 in the treatment of COPD. Dr Hay stated that the compound should be in the clinic within two to three years. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next